CYT 500 Lu 177
Alternative Names: 177Lu-CYT-500Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Cytogen Corporation
- Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Prostate-cancer in USA (Parenteral)
- 28 Feb 2007 Phase-I clinical trials in Prostate cancer in USA (Parenteral)
- 06 Apr 2006 Cytogen Corporation has filed an IND for CYT 500 with the US FDA for Metastatic hormone-refractory prostate cancer